Drug Enforcement Administration September 2019 – Federal Register Recent Federal Regulation Documents

New Single-Sheet Format for U.S. Official Order Form for Schedule I and II Controlled Substances (DEA Form 222)
Document Number: 2019-21021
Type: Rule
Date: 2019-09-30
Agency: Drug Enforcement Administration, Department of Justice
The Drug Enforcement Administration (DEA) is amending its regulations to implement a new single-sheet format for DEA Form 222, used by DEA registrants to order schedules I and II controlled substances. The rule provides for a two-year transition period, during which the existing triplicate version of the forms may continue to be used. The rule also includes a number of minor procedural changes.
John Yolman Salinas, M.D.; Decision and Order
Document Number: 2019-20420
Type: Notice
Date: 2019-09-20
Agency: Drug Enforcement Administration, Department of Justice
Peter J. Waidzunas, D.D.S.; Decision and Order
Document Number: 2019-20418
Type: Notice
Date: 2019-09-20
Agency: Drug Enforcement Administration, Department of Justice
Importer of Controlled Substances Application: Globyz Pharma, LLC
Document Number: 2019-20417
Type: Notice
Date: 2019-09-20
Agency: Drug Enforcement Administration, Department of Justice
Importer of Controlled Substances Registration
Document Number: 2019-20416
Type: Notice
Date: 2019-09-20
Agency: Drug Enforcement Administration, Department of Justice
The registrants listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as importers of schedule I and II controlled substances.
Importer of Controlled Substances Application: Fisher Clinical Services, Inc.
Document Number: 2019-20414
Type: Notice
Date: 2019-09-20
Agency: Drug Enforcement Administration, Department of Justice
Importer of Controlled Substances Application: Fisher Clinical Services, Inc.
Document Number: 2019-20413
Type: Notice
Date: 2019-09-20
Agency: Drug Enforcement Administration, Department of Justice
Importer of Controlled Substances Application: Galephar Pharmaceutical Research Inc.
Document Number: 2019-20412
Type: Notice
Date: 2019-09-20
Agency: Drug Enforcement Administration, Department of Justice
Control of the Immediate Precursor Norfentanyl Used in the Illicit Manufacture of Fentanyl as a Schedule II Controlled Substance
Document Number: 2019-19786
Type: Proposed Rule
Date: 2019-09-17
Agency: Drug Enforcement Administration, Department of Justice
The Drug Enforcement Administration (DEA) proposes to designate the precursor chemical, N-phenyl-N-(piperidin-4- yl)propionamide (norfentanyl) as an immediate precursor for the schedule II controlled substance fentanyl. Furthermore, the DEA proposes to control norfentanyl as a schedule II substance under the Controlled Substances Act (CSA). Norfentanyl is the immediate chemical intermediary in a synthesis process currently used by clandestine laboratory operators for the illicit manufacture of the schedule II controlled substance fentanyl. The distribution of illicitly manufactured fentanyl has caused an unprecedented outbreak of thousands of fentanyl-related overdoses in the United States in recent years. The DEA believes that the control of norfentanyl as a schedule II controlled substance is necessary to prevent its diversion as an immediate chemical intermediary for the illicit production of fentanyl.
Designation of Benzylfentanyl and 4-Anilinopiperidine, Precursor Chemicals Used in the Illicit Manufacture of Fentanyl, as List I Chemicals
Document Number: 2019-19787
Type: Proposed Rule
Date: 2019-09-13
Agency: Drug Enforcement Administration, Department of Justice
The Drug Enforcement Administration (DEA) is proposing the control of N-(1-benzylpiperidin-4-yl)-N-phenylpropionamide (also known as benzylfentanyl), including its salts, and N-phenylpiperidin-4-amine (also known as 4-anilinopiperidine; N-phenyl-4-piperidinamine; 4-AP) (hereinafter referred to as 4-anilinopiperidine), including its amides, its carbamates, and its salts, as list I chemicals under the Controlled Substances Act (CSA). Benzylfentanyl and 4-anilinopiperidine are used in, and are important to, the illicit manufacture of the schedule II controlled substance fentanyl. If finalized, this action would subject handlers of benzylfentanyl and 4-anilinopiperidine to the chemical regulatory provisions of the CSA and its implementing regulations. This rulemaking does not establish a threshold for domestic and international transactions of benzylfentanyl or 4-anilinopiperidine. As such, all transactions of chemical mixtures containing benzylfentanyl or 4- anilinopiperidine will be regulated at any concentration and will be subject to control under the CSA.
Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2020
Document Number: 2019-19785
Type: Notice
Date: 2019-09-12
Agency: Drug Enforcement Administration, Department of Justice
The Drug Enforcement Administration (DEA) proposes to establish the 2020 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.
Jeffrey Stein, M.D.; Decision and Order
Document Number: 2019-19305
Type: Notice
Date: 2019-09-06
Agency: Drug Enforcement Administration, Department of Justice
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.